Rate My Professor Stanley Riddell

Riddell's research centers on the biology of T cells and adoptive immunotherapy, developing genetically reprogrammed T cells using chimeric antigen receptors or T cell receptors to target cancer and pathogen antigens. His lab has advanced techniques for isolating, expanding, modifying, and monitoring therapeutic T cells, identifying optimal naive and memory T cell subsets for superior persistence and antitumor activity. Early work demonstrated antigen-specific T cells preventing cytomegalovirus infections post-transplant, leading to first-in-human trials of leukemia-reactive T cells and CAR T cells of defined composition. Clinical trials under his leadership achieved 93% remission rates in acute lymphoblastic leukemia patients. Key publications include "Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells" (Science Translational Medicine, 2016), "CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients" (Journal of Clinical Investigation, 2016), and "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo" (Leukemia, 2016). Honors include the American Cancer Society Research Professorship (2016) and the Burke O'Reilly Family Endowed Chair in Immunotherapy (2020). His innovations have transformed cancer treatment paradigms.